The European Patent Office's appeal board turned down Novo's last-minute bid to amend its claims, one of two semaglutide patent setbacks MLex reports.
Recap by typeshit. Full story at MLex.
AP sources say FDA scientists opposed the HHS draft telling the agency not to act against pharmacies compounding six wellness peptides. Comments are open for two weeks.
Law firm Frier Levitt reads the rule as single-ingredient only, so the popular blend stays out. Public Citizen and ex-FDA official Janet Woodcock voice safety concerns.
Six peptides can now be compounded under strict conditions, but HHS itself says that proves nothing on safety, and research-use-only sellers stay outside the policy.
Compounders get a pass on BPC-157, TB-500 and four others if they meet sourcing and reporting rules. The Alliance for Pharmacy Compounding cheers it, while Public Citizen calls it reckless.
The once-daily obesity tablet came through an expedited review and can be taken without food rules. Lilly paired a cash price with a discount for many insured users.
MedPage Today
Among 339,092 MS patients, steroid-treated relapses ran 1.85% with GLP-1 use versus 4.84% without, a team from UC Riverside reported at MSToronto2026.
Loading…